Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • 13 hours ago

Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Feb 11, 2026

Quest Diagnostics forecasts 2026 profit, revenue above estimates on lab test demand

Quest Diagnostics on Tuesday forecast 2026 profit and revenue above Wall Street estimates after beating expectations for fourth-quarter results on strong demand for its diagnostic tests.

Reuters • Feb 10, 2026

Quest Diagnostics CEO on using blood testing for Alzheimer's diagnosis

Quest Diagnostics CEO Jim Davis says the company's Alzheimer's testing through blood work can help disagnons the disease a lot sooner and get patients into specialist earlier.

Bloomberg Markets and Finance • Feb 10, 2026

Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call Transcript

Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 10, 2026

Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share.

PRNewsWire • Feb 10, 2026

Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

Fourth quarter revenues of $2.81 billion, up 7.1% from 2024 Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024 Full year revenues of $11.04 billion, up 11.8% from 2024 Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024    Full year cash from operations of $1.89 billion Full year 2026 revenues expected to be between $11.70 billion and $11.82 billion  Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70 SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025.

PRNewsWire • Feb 10, 2026

Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates

Quest Diagnostics (DGX) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.35 per share. This compares to earnings of $2.23 per share a year ago.

Zacks Investment Research • Feb 10, 2026

Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up

DGX tops Q4 EPS and revenue estimates as volumes rise, shares jump premarket, and 2026 guidance points to steady growth.

Zacks Investment Research • Feb 10, 2026

Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Feb 10, 2026